BioLineRx

Yahoo Finance • last month

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Deere & Company (DE [https://seekingalpha.com/symbol/DE]) * First Majestic Silver Corp. (AG [https://seekingalpha.com/... Full story

Yahoo Finance • last month

BioLineRx Q2 2025 Earnings Preview

* BioLineRx (NASDAQ:BLRX [https://seekingalpha.com/symbol/BLRX]) is scheduled to announce Q2 earnings results on Thursday, August 14th, before market open. * The consensus EPS Estimate is -$0.53 [https://seekingalpha.com/symbol/BLRX/ea... Full story

Yahoo Finance • last month

Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth

Company Logo Multiple Myeloma is a cancer affecting plasma cells in bone marrow, often leading to weakened bones, anemia, and kidney damage. The production of abnormal M-proteins is a disease hallmark, detectable in blood or urine. While... Full story

Yahoo Finance • 3 months ago

BioLineRx stock maintains buy rating at H.C. Wainwright on cancer data

H.C. Wainwright reiterated its buy rating and $26.00 price target on BioLineRx (NASDAQ:BLRX), a biotech company currently trading at $4.67, following the company’s presentation of full data from the pilot phase of its CheMo4METPANC Phase 2... Full story

Yahoo Finance • 4 months ago

BioLineRx upgraded to Buy from Hold at JonesResearch

JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot phase data from the investigator-initiated Phase II combination trial of motixafortide plus PD-1 inhibitor cemiplimab plus che... Full story

Yahoo Finance • 2 years ago

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

Management to Hold Conference Call at 10:00 a.m. EDT TEL AVIV, Israel, May 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it... Full story

Yahoo Finance • 2 years ago

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma

- GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints - - Nature Medicine publication describes how GENESIS trial included patients representative of current multiple myeloma population un... Full story

Yahoo Finance • 3 years ago

BLRX 集體訴訟截止日期：業界領先的投資者權益法律事務所 ROSEN 鼓勵 BioLineRx Ltd. 投資者在本所提起證券集體訴訟的重要截止日期 3 月 6 日前尋求法律意見 – BLRX

紐約, March 03, 2023 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒：在 2021 年 2 月 23 日至 2022 年 9 月 19 日（含上述兩日期，簡稱「集體訴訟期」）期間購買了 BioLineRx Ltd. (NASDAQ: BLRX) 證券的人士注意，首席原告的重要截止日期為 2023 年 3 月 6 日。 影響：如果您購買了 BioLine 證券，您可能有權獲得賠償，並且根據後酬約... Full story

Yahoo Finance • 3 years ago

Bragar Eagel &amp; Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Avaya, BioLineRx, Enovix, and Southwest Airlines and Encourages Investors to Contact the Firm

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Avaya Holdings Corp. (NY... Full story

Yahoo Finance • 3 years ago

Glancy Prongay &amp; Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX)

LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased o... Full story

Yahoo Finance • 3 years ago

BLRX, ENVX &amp; NRIA Class Action Reminders: Bronstein, Gewirtz &amp; Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy o... Full story

Yahoo Finance • 3 years ago

DEADLINE ALERT for AVYA, BLRX, ENVX -- Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 3 years ago

DEADLINE ALERT for GOTU, AVAYAQ, BLRX, and ENVX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 3 years ago

BLRX IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclu... Full story

Yahoo Finance • 3 years ago

DEADLINE ALERT for GOTU, AVYA, BLRX, ENVX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 3 years ago

DEADLINE ALERT for GOTU, AVYA, BLRX, and ENVX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 3 years ago

Bragar Eagel &amp; Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Gaotu, Avaya, BioLineRx, and Enovix and Encourages Investors to Contact the Firm

NEW YORK, Feb. 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Gaotu Techedu Inc. (NYSE:... Full story

Yahoo Finance • 3 years ago

ROSEN, A TOP RANKED FIRM, Encourages BioLineRx Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – BLRX

NEW YORK, Feb. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclu... Full story

Yahoo Finance • 3 years ago

DEADLINE ALERT for AVYA, BLRX, ENVX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 3 years ago

BioLineRx Ltd: Please contact the Portnoy Law Firm to recover your losses; March 6, 2023 deadline

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 13, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioLineRx Ltd. (“BioLineRx” or the “Company”) (NASDAQ:BLRX) investors... Full story